Drug Combination Details
| General Information of the Combination (ID: C47122) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Recombinant vaccinia Neu vaccine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Oral cavity/oesophagus/stomach in situ carcinoma
[ICD-11: 2E60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Infiltration of CD4+/CD8+ T lymphocytes | ||||
| In-vivo Model | 6 to 8 weeks old BALB-neuT mice were subcutaneously inoculated in the right flank with 0.2 mL Phosphate-buffered saline (PBS) containing 1*106 SALTO-5 cells. | |||||
| Experimental
Result(s) |
Combined rV-neuT+CUR treatment was more effective at reducing tumor growth and increasing mouse survival, anti-Neu humoral response, and IFN-gamma/IL-2 T-cell release in vitro than the individual treatment. | |||||
